Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2020

View Archived Issues

Universal flu vaccine more challenging than anticipated

Patient genetic variants linked to wound microbiomes

New way to target drugs, independently of drug target

TG-6010, a new vaccinia virus product, demonstrates potent antitumor effects

IND clearance for phase II study of HST-5040 for methylmalonic acidemia and propionic acidemia

Bispecific antibody MEDI-7526 stimulates CD40 and downregulates PD-L1

FDA lifts partial clinical hold on lacutamab TELLOMAK study

Interim data from phase II study of once-weekly setmelanotide formulation

Onxeo reports preclinical data for its new generation molecule, OX-401

IBI-327, a bispecific antibody targeting PD-L1 and OX40 for cancer immunotherapy

SCOHIA initiates phase II study of SCO-792 in diabetic kidney disease

First patient dosed in phase II study of TD-0903 for the treatment of ALI caused by COVID-19

FDA clears first clinical trial of M-5049 in patients with COVID-19 pneumonia

Merck & Co. divulges new hSTING agonists

Imperial College of Science, Technology and Medicine discloses MAP4K4 inhibitors

Novartis presents compounds for arthritis

Byotrol patent describes antiviral phlorotannins

Sage Therapeutics synthesizes GABA-A receptor modulators

Precision model allows accurate cancer therapy testing

Initiation of phase II study of ABI-H2158 in chronic hepatitis B

First patient dosed in phase I study of IMT-002

Discovery of novel orally bioavailable brain-penetrant PRMT5 inhibitor, PRT-811

BGB-11417 demonstrates promising antitumor activities in hematological tumor models

FDA approves Fintepla for seizures in Dravet syndrome

FDA issues complete response letter for abicipar pegol in wet AMD

Noxopharm to study idronoxil for COVID-19 in phase I trial in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...